Results 131 to 140 of about 36,022 (296)

Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Oxytocin has been proposed to exert glucose‐stabilising effects via modulation of pancreatic hormone secretion and to play a role in bone homeostasis. However, human data under controlled conditions are limited. We investigated the effects of intravenously infused oxytocin during a graded glucose infusion on glucose‐regulating hormones and
Vivian Kliim‐Hansen, Ida M. Gether, Aliya M. Thomas, Anne‐Marie Ellegaard, Miriam G. Pedersen, Jens J. Holst, Bolette Hartmann, Filip K. Knop, Lærke S. Gasbjerg, Asger B. Lund   +9 more
wiley   +1 more source

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim, Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon‐Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim, Bong‐Soo Cha   +14 more
wiley   +1 more source

Predicting the Long‐Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN‐1 Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To assess change in long‐term predicted 10‐year cardiometabolic risk (Type 2 diabetes [T2D] and cardiovascular disease [CVD]) in adults with overweight or obesity without T2D. Methods This post hoc analysis used data from ATTAIN‐1, a Phase 3 trial in adults (≥ 18 years) with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 with
Shraddha Shinde, Florian Kahles, Simona Vasileva‐Metodiev, Ryan Griffin, Hong Liu‐Seifert, Jeremie Lebrec, Neena A. Xavier, Runjia Li, Suzanne R. Klise, Ambrish Singh, Jens Aberle   +10 more
wiley   +1 more source

Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the effect of semaglutide on body composition and physical function. Materials and Methods The phase 3b STEP UP trial randomised adults with body mass index ≥ 30 kg/m2 to once‐weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg or placebo for 72 weeks.
Jøran Hjelmesæth, Suhas Bhat, W. Timothy Garvey, Kristoffer Jensen Kolnes, Jennifer Linge, Ildiko Lingvay, Niklas Kahr Rasmussen, Julio Rosenstock, Sean Wharton   +8 more
wiley   +1 more source

Genetically Proxied GIP‐GIPR Pathway Perturbation and Fracture Risk

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To determine whether genetic proxies for incretin pathway perturbation are associated with fracture risk and bone mineral density, providing human genetic evidence relevant to the skeletal safety of incretin‐based therapies. Materials and Methods We conducted drug‐target Mendelian randomisation using cis genetic variants near GIP, GIPR ...
Wenjie Cheng, Weijie Liu, Jie Wei, Chao Zeng, Houchen Lyu, Sizheng Steven Zhao   +5 more
wiley   +1 more source

Kidney Outcomes With GLP‐1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real‐World Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To compare kidney outcomes after GLP‐1 receptor agonists (RA) or tirzepatide (GLP‐1/GIP RAs) versus finerenone initiation in adults with Type 2 diabetes (T2D) and moderate chronic kidney disease (CKD). Methods In a retrospective TriNetX global network study (July 2021–November 2025), adults with T2D and CKD stages 3–4 initiating GLP‐1/GIP ...
Dvora R. Sehtman‐Shachar, Alisa Fishkin, Gil Leibowitz, Ofri Mosenzon, Meir Schechter, Genya Aharon‐Hananel   +5 more
wiley   +1 more source

Acute Effects of Acarbose and Canagliflozin, Alone and in Combination, on Postprandial GLP‐1 and Glycaemic Responses in Post‐Bariatric Hypoglycaemia: A Randomised Crossover Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To evaluate the acute effects of acarbose and canagliflozin, alone and in combination, on postprandial total GLP‐1 and glycaemic responses during a mixed meal test in adults with post‐bariatric hypoglycaemia (PBH). Materials and Methods This single‐centre, randomised, four‐period crossover physiological study included 12 adults with PBH ...
Wei Yang, Anna Kowalka, Lara Jimenez‐Pacheco, Veronica Greener, Kleopatra Alexiadou, Ahmed Ahmed, Julia Kenkre, Chioma Izzi‐Engbeaya, Saira Hameed, Harvinder Chahal, Bernard Khoo, Tricia M.‐M. Tan   +11 more
wiley   +1 more source

Editorial: GIP renaissance

Peptides, 2020
Peter R, Flatt, J Michael, Conlon
openaire   +3 more sources

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

Role of glucagon in metabolic diseases

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes.
Tadahiro Kitamura, Yoko Tabei, Masaki Kobayashi   +2 more
wiley   +1 more source